Synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
=== Specialized reactions === As with all carbonyl compounds, the protons on the α-carbon are labile due to keto–enol tautomerization. Thus, the α-carbon is easily halogenated in the Hell–Volhard–Zelinsky halogenation. The Schmidt reaction converts carboxylic acids to amines. Carboxylic acids are decarboxylated in the Hunsdiecker reaction. The Dakin–West reaction converts an amino acid to the corresponding amino ketone. In the Barbier–Wieland degradation, a carboxylic acid on an aliphatic chain having a simple methylene bridge at the alpha position can have the chain shortened by one carbon. The inverse procedure is the Arndt–Eistert synthesis, where an acid is converted into acyl halide, which is then reacted with diazomethane to give one additional methylene in the aliphatic chain. Many acids undergo oxidative decarboxylation. Enzymes that catalyze these reactions are known as carboxylases (EC 6.4.1) and decarboxylases (EC 4.1.1). Carboxylic acids are reduced to aldehydes via the ester and DIBAL, via the acid chloride in the Rosenmund reduction and via the thioester in the Fukuyama reduction. In ketonic decarboxylation carboxylic acids are converted to ketones. Organolithium reagents (>2 equiv) react with carboxylic acids to give a dilithium 1,1-diolate, a stable tetrahedral intermediate which decomposes to give a ketone upon acidic workup. The Kolbe electrolysis is an electrolytic, decarboxylative dimerization reaction. It gets rid of the carboxyl groups of two acid molecules, and joins the remaining fragments together.
1998 A record for the duration of life among males. The Danish-American Christian Mortensen lived 115 years and 252 days. 1998 Scientists managed to extend, in a laboratory environment, the life of normal human cells beyond the Hayflick limit using telomerase. 1999 Establishment of the Buck Institute for Research on Aging – the first institute originally established primarily to study intervention into the aging process. 1999 Sierra Sciences, a biotechnology company focused on aging research with the goal of curing human aging, was founded by William H. Andrews.
upstream activating sequence (UAS) Also upstream activator sequence and upstream activation sequence. A type of cis-acting regulatory element found in the DNA of yeast such as Saccharomyces cerevisiae, usually a few hundred base pairs upstream of the transcription initiation site within the promoter of a protein-coding gene, which helps to increase the gene's expression by serving as a binding site for transcriptional transactivators, analogous to the function of an enhancer in multicellular eukaryotes.
The strength and flexibility of carbon nanotubes makes them of potential use in controlling other nanoscale structures, which suggests they will have an important role in nanotechnology engineering. The highest tensile strength of an individual multi-walled carbon nanotube has been tested to be 63 GPa. Carbon nanotubes were found in Damascus steel from the 17th century, possibly helping to account for the legendary strength of the swords made of it. Recently, several studies have highlighted the prospect of using carbon nanotubes as building blocks to fabricate three-dimensional macroscopic (>1mm in all three dimensions) all-carbon devices. Lalwani et al. have reported a novel radical initiated thermal crosslinking method to fabricated macroscopic, free-standing, porous, all-carbon scaffolds using single- and multi-walled carbon nanotubes as building blocks. These scaffolds possess macro-, micro-, and nano- structured pores and the porosity can be tailored for specific applications. These 3D all-carbon scaffolds/architectures may be used for the fabrication of the next generation of energy storage, supercapacitors, field emission transistors, high-performance catalysis, photovoltaics, and biomedical devices and implants. CNTs are potential candidates for future via and wire material in nano-scale VLSI circuits. Eliminating electromigration reliability concerns that plague modern Cu interconnects, isolated (single and multi-wall) CNTs can carry current densities in excess of 1000 MA/cm2 without electromigration damage.
Brian Clarke, Artist. For services to Art. Ronald Dennis, , Chair, Podium Analytics and Patron, Tommy's Campaign. For services to Industry and to Charity. Gregory Doran, lately Artistic Director, Royal Shakespeare Company. For services to the Arts. Athelstan Joseph Michael Eavis, , Founder and Leader, Glastonbury Festival. For services to Music and to Charity. Professor William John Edmunds, , Professor, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine. For services to Epidemiology. John Patrick Griffin, Founder, Addison Lee. For services to Business and to Charity. Stephen Alan Michael Hester, Chair, Easyjet and Chair, Nordea. For services to Business and to the Economy. David Charles Holmes, , Chief Executive Officer, Family Action. For services to Children and Families. Professor Amritpal Singh Hungin, , Emeritus Professor of General Practice, Newcastle University. For services to Medicine. Professor John Peter Iredale, , lately Interim Executive Chair, Medical Research Council. For services to Medical Research. The Right Honourable Sajid Javid, , Member of Parliament for Bromsgrove. For Political and Public Service. Timothy Randall Martin, Founder and Chair, Wetherspoons. For services to Hospitality and to Culture. Professor Alexander McCall Smith, , Author and Academic. For services to Literature, to Academia and to Charity Professor Neil James McCready Mortensen, lately President, Royal College of Surgeons of England. For services to Surgery. Gerald Maurice Ronson, , For services to Philanthropy and to the Jewish Community.
Sources: en.wikipedia.org
The shark population has benefited significantly from the surge in seal numbers following the Marine Mammal Protection Act in 1972, and as many as 800 individual white sharks are documented visiting the Cape Cod area.
== Political implications == Allenby and Garreau propose that the Great Chain of Being, as developed within medieval Christian thought, helped legitimize political hierarchy and discourage rebellion for centuries. Both Catholic and later Protestant rulers appealed to this worldview. For example, the Protestant King James I himself wrote, "The state of monarchy is the most supreme thing upon earth: for kings are not only God's Lieutenants upon earth, and sit upon God's throne, but even by God himself they are called Gods."
=== Translation === Ninety of the Bloomberg tablets have been translated. This is the highest number of translated artefacts from any comparable archaeological site in London, surpassing the previous record of 19. Alongside the 90 translated tablets are another 91 stylus tablets, all which have been inscribed but are considered illegible. The 90 translated tablets have been grouped according to the content translated within, 43 of these tablets contained general correspondence, 25 of them were financial or legal documentation, 8 tablets were book keeping accounts showing what people owed and the remaining 14 are miscellaneous. The tablets were translated by Dr Roger Tomlin, an expert in Roman cursive, the writing style in which the tablets were written. Tablets vary in content, including the oldest financial document from London (dating to 8 January 57 AD), about 3 to 4 years before the city was destroyed by Boudica. It also documents how the Roman government responded with their military and how soon the city recovered thereafter. Legal documents include a judge calling a pretrial hearing, and educational material. One tablet shows the alphabet written out, indicating the presence of perhaps the first school in Britain. Additionally, among the tablets there are over 100 names of people of all different professions and social classes who lived in London at the time, such as slaves, merchants, soldiers, and politicians. One prominent figure that is named is Julius Classicus, who was a commander in the Roman auxiliaries.
=== IRAP catalytic site inhibitors === Peptidomimetics The first reported IRAP inhibitors were designed as angiotensin IV (AngIV) analogs. In 2006, Axén et al published a macrocyclized version of an AngIV derivative (Compound 1) which confers metabolic stability together with high affinity for IRAP (Ki = 25.8 nM). Under a similar scope Lukaszuk et al produced compound AL-11, which was able to inhibit IRAP (Ki = 27.5 nM) and displayed around 200-fold selectivity over APN. Further structural modifications on the AngIV-based inhibitors from Anderson et al led to optimized macrocycle HA08 (available crystal structure within IRAP, Figure 2) with excellent IRAP potency (Ki = 3.3 nM) and selectivity over APN, but poor metabolic stability.
Thyroid hormones are two hormones produced and released by the thyroid gland: triiodothyronine (T3) and thyroxine (T4). They are tyrosine-based hormones that are primarily responsible for regulation of metabolism. T3 and T4 are partially composed of iodine, which is derived from food. A deficiency of iodine leads to decreased production of T3 and T4, enlarges the thyroid tissue, and causes the disease known as simple goitre. The major form of thyroid hormone in the blood is thyroxine (T4), whose half-life of around one week is longer than that of T3. In humans, the ratio of T4 to T3 released into the blood is approximately 14:1. T4 is converted to the active T3 (three to four times more potent than T4) within cells by deiodinases (5′-deiodinase). These are further processed by decarboxylation and deiodination to produce iodothyronamine (T1a) and thyronamine (T0a). All three isoforms of the deiodinases are selenium-containing enzymes, thus dietary selenium is essential for T3 production. Calcitonin, a peptide hormone produced and secreted by the thyroid, is usually not included in the meaning of "thyroid hormone". Thyroid hormones are one of the factors responsible for the modulation of energy expenditure. This is achieved through several mechanisms, such as mitochondrial biogenesis and adaptive thermogenesis. American chemist Edward Calvin Kendall was responsible for the isolation of thyroxine in 1915. In 2020, levothyroxine, a manufactured form of thyroxine, was the second most commonly prescribed medication in the United States, with more than 98 million prescriptions.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.